Table 1.
Patient and disease characteristics by response to chemotherapya
| Characteristic | Responders (N=17) | Non-responders (N=35) | Total (N=52) | P-value |
|---|---|---|---|---|
| Age | 0.81 | |||
| Median (min to Max) | 42 (25–62) yr | 42 (6–70) yr | 42 (6 to70) yr | |
| Gender | 0.37 | |||
| Male | 11 (37.9%) | 18 (62.1%) | 29 (55.8%) | |
| Female | 6 (26.1%) | 17 (73.9%) | 23 (44.2%) | |
| Ethnicity | 0.24 | |||
| White | 16 (37.2%) | 27 (62.8%) | 43 (82.7%) | |
| Other | 1 (11.1%) | 8 (88.9%) | 9 (17.3%) | |
| Tumor size | 0.39 | |||
| Median (min to max) | 5.5 (2–18) cm | 8.0 (1–15) cm | 7.2 (1–18) cm | |
| Tumor type | 0.90 | |||
| Pheochromocytoma | 6 (31.6%) | 13 (68.4%) | 19 (36.5%) | |
| Paraganglioma | 11 (33.3%) | 22 (66.7%) | 33 (63.5%) | |
| Metastasis timing | 0.91 | |||
| Synchronous | 10 (33.3%) | 20 (66.7%) | 30 (57.7%) | |
| Metachronous | 7 (31.8%) | 15 (68.2%) | 23 (42.3%) | |
| Sites of metastasisb | ||||
| Single site of metastasis | 4 (44.4%) | 5 (55.5%) | 9 (16.9%) | 0.40 |
| Multiple sites of metastases | 13 (30.2%) | 30 (69.7%) | 43 (82.6%) |
a
Data are number of patients (%) unless otherwise specified,
b
Number of sites of metastasis at the start of chemotherapy,
c
24 patients in the Non-responders group had Not Available biochemical studies;